The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway

Brain, Behavior, and Immunity

Volumn 48, Issue , 2015, Pages 48-52

  Guloksuz, Sinan ^a,b   Arts, Baer ^a   Walter, Sharon ^a   Drukker, Marjan ^a   Rodriguez, Laura ^a   Myint, Aye Mu ^a,c   Schwarz, Markus J ^c   Ponds, Rudolf ^a   van Os, Jim ^a,d   Kenis, Gunter ^a   Rutten, Bart P F ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; ECT; Immune; Indoleamine 2,3 dioxygenase; Kynurenic acid; Kynurenine; Kynurenine amino transferases; Neuroprotection; Tryptophan

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; 5 HYDROXYINDOLEACETIC ACID; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN; 3-HYDROXYKYNURENINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; TIME TO TREATMENT; TREATMENT RESPONSE; TRYPTOPHAN KYNURENINE METABOLIC PATHWAY; ANALOGS AND DERIVATIVES; BLOOD; DEPRESSIVE DISORDER; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; YOUNG ADULT;

ADULT; AGED; DEPRESSIVE DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TRYPTOPHAN; YOUNG ADULT;

EID: 84942981227     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.02.029     Document Type: Article

References (32)

1. Abbott, C.C., Gallegos, P., Rediske, N., Lemke, N.T., Quinn, D.K., 2014. A review of longitudinal electroconvulsive therapy: neuroimaging investigations. J. Geriatr. Psychiatry Neurol. 27, 33-46.
2. Baldinger, P., Lotan, A., Frey, R., Kasper, S., Lerer, B., Lanzenberger, R., 2014. Neurotransmitters and electroconvulsive therapy. J. ECT 30, 116-121.
3. Dantzer, R., O'Connor, J.C., Lawson, M.A., Kelley, K.W., 2011. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36, 426-436.
4. de Jong, J.O., Arts, B., Boks, M.P., Sienaert, P., van den Hove, D.L., Kenis, G., van Os, J., Rutten, B.P., 2014. Epigenetic effects of electroconvulsive seizures. J. ECT 30, 152-159.
5. Fluitman, S.B., Heijnen, C.J., Denys, D.A., Nolen, W.A., Balk, F.J., Westenberg, H.G., 2011. Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J. Affect. Disord. 131, 388-392.
6. Guloksuz, S., Rutten, B.P., Arts, B., van Os, J., Kenis, G., 2014. The immune system and electroconvulsive therapy for depression. J. ECT 30, 132-137.
7. Haskett, R.F., 2014. Electroconvulsive therapy's mechanism of action: neuroendocrine hypotheses. J. ECT 30, 107-110.
8. Herve, C., Beyne, P., Jamault, H., Delacoux, E., 1996. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. B 675, 157-161.
9. Hestad, K.A., Tonseth, S., Stoen, C.D., Ueland, T., Aukrust, P., 2003. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 19, 183-188.
10. Hoekstra, R., van den Broek, W.W., Fekkes, D., Bruijn, J.A., Mulder, P.G., Pepplinkhuizen, L., 2001. Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. Psychiatry Res. 103, 115-123.
11. Kirkegaard, C., Moller, S.E., Bjorum, N., 1978. Addition of L-tryptophan to electroconvulsive treatment in endogenous depression. A double-blind study. Acta Psychiatr. Scand. 58, 457-462.
12. Kocki, T., Wnuk, S., Kloc, R., Kocki, J., Owe-Larsson, B., Urbanska, E.M., 2012. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. J. Neural Transm. 119, 235-243.
13. Lehtimaki, K., Keranen, T., Huuhka, M., Palmio, J., Hurme, M., Leinonen, E., Peltola, J., 2008. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J. ECT 24, 88-91.
14. Mokhtar, A.S., Morgan, C.J., Bradley, D.M., Badawy, A.A., 1997. No early effects of electroconvulsive therapy on tryptophan metabolism and disposition in endogenous depression. Biol. Psychiatry 42, 201-205.
15. Myint, A.M., 2012a. AS15-02 - Antidepressants and anti-inflammatory agents on immune-kynurenine pathway: results from in-vitro studies. Eur. Psychiatry 27, 1.
16. Myint, A.M., 2012b. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 279, 1375-1385.
17. Myint, A.M., Bondy, B., Baghai, T.C., Eser, D., Nothdurfter, C., Schule, C., Zill, P., Muller, N., Rupprecht, R., Schwarz, M.J., 2013. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav. Immun. 31, 128-133.
18. Myint, A.M., Kim, Y.K., 2003. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61, 519-525.
19. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., 2007. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98, 143-151.
20. Myint, A.M., Schwarz, M.J., Muller, N., 2012. The role of the kynurenine metabolism in major depression. J. Neural Transm. 119, 245-251.
21. Oades, R.D., Dauvermann, M.R., Schimmelmann, B.G., Schwarz, M.J., Myint, A.M., 2010a. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism-effects of medication. Behav. Brain Funct. 6, 29.
22. Oades, R.D., Myint, A.M., Dauvermann, M.R., Schimmelmann, B.G., Schwarz, M.J., 2010b. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav. Brain Funct. 6, 32.
23. Ongur, D., Heckers, S., 2004. A role for glia in the action of electroconvulsive therapy. Harv. Rev. Psychiatry 12, 253-262.
24. Palmio, J., Huuhka, M., Saransaari, P., Oja, S.S., Peltola, J., Leinonen, E., Suhonen, J., Keranen, T., 2005. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res. 137, 183-190.
25. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., 2010. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15, 393-403.
26. Rotter, A., Biermann, T., Stark, C., Decker, A., Demling, J., Zimmermann, R., Sperling, W., Kornhuber, J., Henkel, A., 2013. Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. J. ECT.
27. Sienaert, P., 2014. Mechanisms of ECT: reviewing the science and dismissing the myths. J. ECT 30, 85-86.
28. Simes, R.J., 1986. An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751-754.
29. StataCorp, 2011. Stata/SE Statistical Software, Release 12. StataCorp LP, College Station, TX.
30. Whalley, L.J., Yates, C.M., Christie, J.E., 1980. Effect of electroconvulsive therapy (ECT) on plasma tryptophan. Psychol. Med. 10, 377-380.
31. Wichers, M.C., Koek, G.H., Robaeys, G., Verkerk, R., Scharpe, S., Maes, M., 2005. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 10, 538-544.
32. Zunszain, P.A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A.M., Thuret, S., Price, J., Pariante, C.M., 2012. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37, 939-949.